ARIA : Summary for ARIAD Pharmaceuticals, Inc. - Yahoo Finance

U.S. Markets close in 5 hrs 31 mins

ARIAD Pharmaceuticals, Inc. (ARIA)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
23.990.00 (0.00%)
As of 5:00PM EDT. Market open.
People also watch
ARNAARRYEXELACHNACAD
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close23.99
Open0.00
Bid0.00 x
Ask0.00 x
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. VolumeN/A
Market Cap
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals19 days ago

    Former Ariad CEO joins a familiar face on board of The Medicines Co., hinting at a sale

    The former CEO of Ariad Pharmaceuticals Inc., who spent the last year shaping up the Cambridge-based drug company for its $5.2 acquisition earlier this year, was just named to the board of a new biotech last week. There, as the newest board member of New Jersey-based The Medicines Company, Paris Panayiotopoulos joins a familiar face: Alex Denner, former chairman of Ariad (ARIA). The founder of hedge fund Sarissa Capital, an activist investor believed to have played a big role in orchestrating the sale of that company, was named to that same 11-member board just over a year ago.

  • Investopedia26 days ago

    Amgen's Blincyto sBLA Secures FDA Priority Review

    Amgen aims to expand the use of Blincyto for more indications of acute lymphoblastic leukemia

  • Market Realist2 months ago

    Who Is Incyte Collaborating With?

    Incyte’s (INCY) Jakafi is distributed in the United States through a network of specialty pharmacy providers and wholesalers for direct delivery.